Last reviewed · How we verify

NCT05095025

PENG: an Estimation of ED50 in Neck of Femur Fracture

Status unknown NA Last updated 27 October 2021
What this trial tests

NA trial testing Bupivacaine Hydrochloride 20ml injectate in Hip Fractures in 50 participants. Status unknown.

Timeline
14 September 2021
Primary endpoint
1 September 2022
1 October 2022

Quick facts

Lead sponsorUniversity College Cork
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsequential
Maskingnone
Primary purposetreatment
Enrollment50
Start date14 September 2021
Primary completion1 September 2022
Estimated completion1 October 2022
Sites1 location across Ireland

Drugs / interventions tested

Conditions studied

Sponsor

University College Cork

Who can join

18 and older, any sex, with Hip Fractures or Pain, Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The effective dose of local anaesthetic used in PENG blocks to achieve analgesia in patients with fractured neck of femur is unknown. It is planned to address this question using a dixon/massey sequential dosing methodology to establish the ED50 of 0.25% Bupivacaine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hip Fractures

Currently open trials in the same condition.

Other University College Cork trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05095025.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing